NWPF

Search Results Tagged With clinical trial

New Digital Cognitive Assessment Tool Receives Positive FDA Review

https://nwpf.org/stay-informed/news/new-digital-cognitive-assessment-tool-receives-positive-fda-review/

The cognitive science company Cogstate received approval to market a new digital cognitive assessment tool to assist healthcare professionals in measuring cognition in patients ages 6 to 99, either in…
July 31, 2017

Parkinson's stem cell therapy OK'd for testing

https://nwpf.org/stay-informed/news/parkinsons-stem-cell-therapy-okd-for-testing/

In what appears to be a medical first, a stem cell-based treatment for the root cause of Parkinson’s disease has been accepted for human testing. The Australian government’s approval for Carlsbad-bas…
December 14, 2015

Research paves way for clinical trials of cell therapies to treat Parkinson's disease, spinal cord injury

https://nwpf.org/stay-informed/news/research-paves-way-for-clinical-trials-of-cell-therapies-to-treat-parkinsons-disease-spinal-cord-injury/

Stem cells that have been specifically developed for use as clinical therapies are fit for use in patients, an independent study of their genetic make-up suggests.
November 26, 2015

FAU to host potentially groundbreaking drug trial for Lewy body disease

https://nwpf.org/stay-informed/news/fau-to-host-potentially-groundbreaking-drug-trial-for-lewy-body-disease/

Currently, Lewy body patients often are treated with drugs designed for Alzheimer's disease. The HEADWAY-DLB (dementia with Lewy bodies) study, being conducted by Bermuda-based Axovant Sciences at FAU…
February 28, 2016

FDA lifts clinical hold on NeuroDerm's ND0612 to treat Parkinson's disease

https://nwpf.org/stay-informed/news/fda-lifts-clinical-hold-on-neuroderms-nd0612-to-treat-parkinsons-disease/

The US Food and Drug Administration (FDA) has lifted the clinical hold on Israeli pharmaceutical firm NeuroDerm's US clinical studies of its primary product candidates, ND0612H and ND0612L, which are…
May 11, 2015

2 Markers of Parkinson’s Progression May Help Trials in Newly Diagnosed Patients

https://nwpf.org/stay-informed/news/2-markers-of-parkinson-s-progression-may-help-trials-in-newly-diagnosed-patients/

A five year study by the Movement Disorder Society found that dopaminergic  (levadopa & dopamine agonists) were evaluated in participants in 2 ways: on and off-time periods, while findings for the…
April 11, 2018

<< Back 1 - 6 of 6 Next >>